세계의 표적화 리포좀 약물 전달 시장 보고서 : 동향, 예측 및 경쟁 분석(-2030년)

Targeted Liposomes Drug Delivery Trends and Forecast

The future of the global targeted liposomes drug delivery market looks promising with opportunities in the fungal infection therapy and cancer therapy markets. The global targeted liposomes drug delivery market is expected to reach an estimated $4.1 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are rising rates of chronic illnesses including cancer and fungus-related infections, enhanced knowledge and consciousness of the body's medication metabolism and absorption processes, and rising adoption of novel therapeutic approaches.

A more than 150-page report is developed to help in your business decisions.

Targeted Liposomes Drug Delivery by Segment

The study includes a forecast for the global targeted liposomes drug delivery by type, application, and region.

Targeted Liposomes Drug Delivery Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Liposomal Doxorubicin
• Liposomal Paclitaxel
• Liposomal Amphotericin B
• Others

Targeted Liposomes Drug Delivery Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Fungal Infection Therapy
• Cancer Therapy
• Others

Targeted Liposomes Drug Delivery Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Targeted Liposomes Drug Delivery Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies targeted liposomes drug delivery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the targeted liposomes drug delivery companies profiled in this report include-

• Catalent
• Pacira Pharmaceuticals
• Baxter
• Lonza
• Evonik
• Merck
• Fareva
• Vetter
• Polymun Scientific Immunbiologische Forschung
• Recipharm

Targeted Liposomes Drug Delivery Market Insights

Lucintel forecasts that liposomal doxorubicin is expected to witness highest growth over the forecast period due to the rising incidence rate of cancers.

North America will remain the largest segment over the forecast period due to the higher cancer incidence and more sophisticated medical facilities.

Features of the Global Targeted Liposomes Drug Delivery Market

Market Size Estimates: Targeted liposomes drug delivery market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Targeted liposomes drug delivery market size by type, application, and region in terms of value ($B).

Regional Analysis: Targeted liposomes drug delivery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the targeted liposomes drug delivery market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the targeted liposomes drug delivery market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the targeted liposomes drug delivery market size?

Answer: The global targeted liposomes drug delivery market is expected to reach an estimated $4.1 billion by 2030.

Q2. What is the growth forecast for targeted liposomes drug delivery market?

Answer: The global targeted liposomes drug delivery market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the targeted liposomes drug delivery market?

Answer: The major drivers for this market are rising rates of chronic illnesses including cancer and fungus-related infections, enhanced knowledge and consciousness of the body's medication metabolism and absorption processes, and rising adoption of novel therapeutic approaches.

Q4. What are the major segments for targeted liposomes drug delivery market?

Answer: The future of the global targeted liposomes drug delivery market looks promising with opportunities in the fungal infection therapy and cancer therapy markets.

Q5. Who are the key targeted liposomes drug delivery market companies?

Answer: Some of the key targeted liposomes drug delivery companies are as follows.

• Catalent
• Pacira Pharmaceuticals
• Baxter
• Lonza
• Evonik
• Merck
• Fareva
• Vetter
• Polymun Scientific Immunbiologische Forschung
• Recipharm

Q6. Which targeted liposomes drug delivery market segment will be the largest in future?

Answer: Lucintel forecasts that liposomal doxorubicin is expected to witness highest growth over the forecast period due to the rising incidence rate of cancers.

Q7. In targeted liposomes drug delivery market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to the higher cancer incidence and more sophisticated medical facilities.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the targeted liposomes drug delivery market by type (liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others), application (fungal infection therapy , cancer therapy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Targeted Liposomes Drug Delivery Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Targeted Liposomes Drug Delivery Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Targeted Liposomes Drug Delivery Market by Type
  • 3.3.1: Liposomal Doxorubicin
  • 3.3.2: Liposomal Paclitaxel
  • 3.3.3: Liposomal Amphotericin B
  • 3.3.4: others
• 3.4: Global Targeted Liposomes Drug Delivery Market by Application
  • 3.4.1: Fungal Infection Therapy
  • 3.4.2: Cancer Therapy
  • 3.4.3: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Targeted Liposomes Drug Delivery Market by Region
• 4.2: North American Targeted Liposomes Drug Delivery Market
  • 4.2.2: North American Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
• 4.3: European Targeted Liposomes Drug Delivery Market
  • 4.3.1: European Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
  • 4.3.2: European Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
• 4.4: APAC Targeted Liposomes Drug Delivery Market
  • 4.4.1: APAC Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
  • 4.4.2: APAC Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
• 4.5: ROW Targeted Liposomes Drug Delivery Market
  • 4.5.1: ROW Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
  • 4.5.2: ROW Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Type
  • 6.1.2: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Application
  • 6.1.3: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Region
• 6.2: Emerging Trends in the Global Targeted Liposomes Drug Delivery Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Targeted Liposomes Drug Delivery Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Targeted Liposomes Drug Delivery Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Catalent
• 7.2: Pacira Pharmaceuticals
• 7.3: Baxter
• 7.4: Lonza
• 7.5: Evonik
• 7.6: Merck
• 7.7: Fareva
• 7.8: Vetter
• 7.9: Polymun Scientific Immunbiologische Forschung
• 7.10: Recipharm